{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:24:24Z","timestamp":1793823864105,"version":"4.6.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.survophthal.2023.09.007","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T16:40:39Z","timestamp":1695919239000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Ocular toxicities of fibroblast growth factor receptor inhibitors: A review"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0365-7214","authenticated-orcid":false,"given":"Jerry","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine H.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5358-2257","authenticated-orcid":false,"given":"Sumayya","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.survophthal.2023.09.007_bib1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.survophthal.2023.09.007_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.lungcan.2022.08.016","article-title":"Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: the SAKK 19\/18 phase II study","volume":"172","author":"Addeo","year":"2022","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.survophthal.2023.09.007_bib3","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jtho.2019.05.041","article-title":"SWOG S1400D (NCT02965378), a phase II study of the fibroblast growth factor receptor inhibitor AZD4547 in previously treated patients with fibroblast growth factor pathway-activated stage IV squamous cell lung cancer (Lung-MAP Substudy)","volume":"14","author":"Aggarwal","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.survophthal.2023.09.007_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40942-021-00305-9","article-title":"Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma","volume":"7","author":"Alekseev","year":"2021","journal-title":"Int J Retina Vitreous"},{"issue":"16","key":"10.1016\/j.survophthal.2023.09.007_bib5","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.survophthal.2023.09.007_bib6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","article-title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors","volume":"31","author":"Bahleda","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.survophthal.2023.09.007_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jfo.2020.03.018","article-title":"Reversible corneal stromal thinning, acute-onset white cataract and angle-closure glaucoma due to erdafitinib, a fibroblast growth factor receptor inhibitor: report of three cases","volume":"44","author":"Bauters","year":"2021","journal-title":"J Fr Ophtalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2023.09.007_bib8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamadermatol.2017.0500","article-title":"Severe onycholysis and eyelash trichomegaly following use of new selective pan-FGFR inhibitors","volume":"153","author":"B\u00e9trian","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.survophthal.2023.09.007_bib9","first-page":"1167","article-title":"Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review","volume":"21","author":"Borkar","year":"2013","journal-title":"Support Care Cancer"},{"issue":"21","key":"10.1016\/j.survophthal.2023.09.007_bib10","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1200\/JCO.19.02630","article-title":"Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W","volume":"38","author":"Chae","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.survophthal.2023.09.007_bib11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/ceo.13940","article-title":"Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1-3 tyrosine kinase inhibitor anticancer therapy","volume":"49","author":"Charng","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2023.09.007_bib12","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1038\/s41467-022-30666-0","article-title":"Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer","volume":"13","author":"Coombes","year":"2022","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.survophthal.2023.09.007_bib13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jdcr.2020.04.013","article-title":"Severe onycholysis and eyelash trichomegaly in a patient treated with erdafitinib","volume":"6","author":"Deutsch","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.survophthal.2023.09.007_bib14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.joco.2019.05.002","article-title":"Ocular adverse events with immune checkpoint inhibitors","volume":"31","author":"Fang","year":"2019","journal-title":"J Curr Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2023.09.007_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/diagnostics12020249","article-title":"Choroidal and choriocapillaris morphology in pan-FGFR inhibitor-associated retinopathy: a case report","volume":"12","author":"Fasolino","year":"2022","journal-title":"Diagnostics"},{"issue":"7","key":"10.1016\/j.survophthal.2023.09.007_bib16","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40265-021-01507-z","article-title":"Ocular toxicity of targeted anticancer agents","volume":"81","author":"Fortes","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.survophthal.2023.09.007_bib17","doi-asserted-by":"crossref","first-page":"101657","DOI":"10.1016\/j.ajoc.2022.101657","article-title":"Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibition","volume":"27","author":"Foulsham","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"9","key":"10.1016\/j.survophthal.2023.09.007_bib18","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ophtha.2021.05.012","article-title":"Re: Magone et al.: ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor (Ophthalmology. 2021;128:624-626)","volume":"128","author":"Francis","year":"2021","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.survophthal.2023.09.007_bib19","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","article-title":"Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy","volume":"124","author":"Francis","year":"2017","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.survophthal.2023.09.007_bib20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamaophthalmol.2021.3331","article-title":"Clinical and morphologic characteristics of fibroblast growth factor receptor inhibitor-associated retinopathy","volume":"139","author":"Francis","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2023.09.007_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.survophthal.2023.09.007_bib22","doi-asserted-by":"crossref","unstructured":"Houghton O.M. Irreversible retinal pigment epithelium toxicity associated with fibroblast growth factor receptor inhibitor therapy. Retin Cases Brief Rep. 2022. https:\/\/doi.org\/10.1097\/ICB.0000000000001354. Online ahead of print.","DOI":"10.1097\/ICB.0000000000001354"},{"issue":"1","key":"10.1016\/j.survophthal.2023.09.007_bib23","doi-asserted-by":"crossref","first-page":"e0005","DOI":"10.1097\/coa.0000000000000005","article-title":"Corneal melt associated with cancer immunotherapy","volume":"2","author":"Hsu","year":"2023","journal-title":"Cornea Open"},{"issue":"7","key":"10.1016\/j.survophthal.2023.09.007_bib24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/002215549704500710","article-title":"Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues","volume":"45","author":"Hughes","year":"1997","journal-title":"J Histochem Cytochem"},{"issue":"10","key":"10.1016\/j.survophthal.2023.09.007_bib25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.survophthal.2023.09.007_bib26","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1055\/a-1403-3068","article-title":"Drug-induced pseudo-central serous chorioretinopathy in carcinoma patients","volume":"238","author":"Jung","year":"2021","journal-title":"Klin Monbl Augenheilkd"},{"issue":"2","key":"10.1016\/j.survophthal.2023.09.007_bib27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s10637-018-0648-z","article-title":"A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor","volume":"37","author":"Kelly","year":"2019","journal-title":"Investig New Drugs"},{"issue":"4","key":"10.1016\/j.survophthal.2023.09.007_bib28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/24741264211013629","article-title":"Fibroblast growth factor receptor inhibitor\u2013associated multifocal serous retinal detachments: a case report","volume":"6","author":"Kim","year":"2022","journal-title":"J Vitreo Retin Dis"},{"issue":"5","key":"10.1016\/j.survophthal.2023.09.007_bib29","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s11523-019-00670-4","article-title":"First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer","volume":"14","author":"Kim","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.survophthal.2023.09.007_bib30","first-page":"149","article-title":"Fibroblast growth factor receptor (FGFR) and candidate signaling molecule distribution within rat and human retina","volume":"8","author":"Kinkl","year":"2002","journal-title":"Mol Vis"},{"issue":"13","key":"10.1016\/j.survophthal.2023.09.007_bib31","first-page":"3418","article-title":"Expression of fibroblast growth factor receptors (FGFR 1\u20135) in fetal and adult human retina","volume":"45","author":"Kirby","year":"2004","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.survophthal.2023.09.007_bib32","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.survophthal.2023.09.007_bib33","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/cas.14265","article-title":"First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors","volume":"111","author":"Koyama","year":"2020","journal-title":"Cancer Sci"},{"issue":"15_suppl","key":"10.1016\/j.survophthal.2023.09.007_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.3620","article-title":"Pan-cancer analysis of FGFR1-3 genomic alterations to reveal a complex molecular landscape","volume":"38","author":"Krook","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.survophthal.2023.09.007_bib35","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.lungcan.2019.12.018","article-title":"A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma","volume":"140","author":"Lam","year":"2020","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.survophthal.2023.09.007_bib36","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-21-2664","article-title":"Infigratinib in patients with recurrent gliomas and FGFR alterations: a multicenter phase II study","volume":"28","author":"Lassman","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.survophthal.2023.09.007_bib37","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.survophthal.2023.09.007_bib38","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ophtha.2020.08.026","article-title":"Ocular adverse effects of infigratinib, a new fibroblast growth factor receptor tyrosine kinase inhibitor","volume":"128","author":"Magone","year":"2021","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2023.09.007_bib39","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.survophthal.2023.09.007_bib40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11523-017-0502-9","article-title":"A phase 1 study of LY2874455, an oral selective pan-FGFR inhibitor, in patients with advanced cancer","volume":"12","author":"Michael","year":"2017","journal-title":"Target Oncol"},{"issue":"3","key":"10.1016\/j.survophthal.2023.09.007_bib41","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10637-017-0514-4","article-title":"Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors","volume":"36","author":"Nishina","year":"2018","journal-title":"Investig New Drugs"},{"issue":"2","key":"10.1016\/j.survophthal.2023.09.007_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.survophthal.2023.09.007_bib43","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1158\/1078-0432.CCR-17-0645","article-title":"A phase Ib open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers","volume":"23","author":"Paik","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.survophthal.2023.09.007_bib44","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/bjc.2017.330","article-title":"A phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours","volume":"117","author":"Papadopoulos","year":"2017","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.survophthal.2023.09.007_bib45","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jamaophthalmol.2020.2778","article-title":"Fibroblast growth factor receptor inhibitor-associated retinopathy","volume":"138","author":"Parikh","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2023.09.007_bib46","first-page":"57","article-title":"Reversible retinopathy associated with fibroblast growth factor receptor inhibitor","volume":"13","author":"Patel","year":"2022","journal-title":"COP"},{"issue":"2","key":"10.1016\/j.survophthal.2023.09.007_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2474126417751724","article-title":"Reversible macular lesions in the setting of oral pan-fibroblast growth factor inhibitor for the treatment of bladder cancer","volume":"2","author":"Prensky","year":"2018","journal-title":"J Vitreo Retin Dis"},{"issue":"2","key":"10.1016\/j.survophthal.2023.09.007_bib48","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.oret.2020.10.005","article-title":"Pseudovitelliform maculopathy associated with FGFR inhibitor therapy","volume":"5","author":"Ramtohul","year":"2021","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"10.1016\/j.survophthal.2023.09.007_bib49","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.semcdb.2006.10.002","article-title":"An essential role for FGF receptor signaling in lens development","volume":"17","author":"Robinson","year":"2006","journal-title":"Semin Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.survophthal.2023.09.007_bib50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/(SICI)1097-0177(199604)205:4<379::AID-AJA2>3.0.CO;2-F","article-title":"Fibroblast growth factor signalling in the hair growth cycle: expression of the fibroblast growth factor receptor and ligand genes in the murine hair follicle","volume":"205","author":"Rosenquist","year":"1996","journal-title":"Dev Dyn"},{"issue":"4","key":"10.1016\/j.survophthal.2023.09.007_bib51","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10637-016-0416-x","article-title":"Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a phase I study","volume":"35","author":"Saka","year":"2017","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.survophthal.2023.09.007_bib52","doi-asserted-by":"crossref","DOI":"10.25270\/con.2020.12.00003","article-title":"Bilateral serous epithelial detachment after starting therapy with erdafitinib","author":"Sauerzopf","year":"2020","journal-title":"Consultant [Internet]"},{"issue":"10","key":"10.1016\/j.survophthal.2023.09.007_bib53","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.survophthal.2023.09.007_bib54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12886-019-1285-9","article-title":"Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors","volume":"20","author":"Shin","year":"2020","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2023.09.007_bib55","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.survophthal.2023.09.007_bib56","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/annonc\/mdw100","article-title":"Ocular toxicities of MEK inhibitors and other targeted therapies","volume":"27","author":"Stjepanovic","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.survophthal.2023.09.007_bib57","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"issue":"30","key":"10.1016\/j.survophthal.2023.09.007_bib58","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.survophthal.2023.09.007_bib59","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdv591","article-title":"A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.survophthal.2023.09.007_bib60","doi-asserted-by":"crossref","first-page":"100818","DOI":"10.1016\/j.ajoc.2020.100818","article-title":"Trichiasis and dry eye syndrome in two patients on novel fibroblast growth factor receptor inhibitor therapies","volume":"19","author":"Vinson","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"9","key":"10.1016\/j.survophthal.2023.09.007_bib61","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-18-1959","article-title":"A phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor Debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations","volume":"25","author":"Voss","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.survophthal.2023.09.007_bib62","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.survophthal.2023.09.007_bib63","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1177\/1078155220983425","article-title":"Fibroblast growth factor receptor (FGFR) inhibitors: a review of a novel therapeutic class","volume":"27","author":"Weaver","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"10.1016\/j.survophthal.2023.09.007_bib64","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10637-019-00780-w","article-title":"A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies","volume":"38","author":"Yamamoto","year":"2020","journal-title":"Investig New Drugs"},{"issue":"6","key":"10.1016\/j.survophthal.2023.09.007_bib65","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1083\/jcb.200910126","article-title":"Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis","volume":"188","author":"Yang","year":"2010","journal-title":"J Cell Biol"},{"issue":"1","key":"10.1016\/j.survophthal.2023.09.007_bib66","doi-asserted-by":"crossref","first-page":"e0117089","DOI":"10.1371\/journal.pone.0117089","article-title":"Fibroblast growth factor receptor 2 (FGFR2) is required for corneal epithelial cell proliferation and differentiation during embryonic development","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.survophthal.2023.09.007_bib67","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ydbio.2008.03.028","article-title":"Fibroblast growth factor receptor signaling is essential for lens fiber cell differentiation","volume":"318","author":"Zhao","year":"2008","journal-title":"Dev Biol"},{"issue":"1","key":"10.1016\/j.survophthal.2023.09.007_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.survophthal.2023.09.007_bib69","unstructured":"212018s000lbl.pdf [Internet]. [cited 2023 January 16]. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212018s000lbl.pdf\u3009."},{"key":"10.1016\/j.survophthal.2023.09.007_bib70","unstructured":"214622s000lbl.pdf [Internet]. [cited 2023 January 16]. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214622s000lbl.pdf\u3009."},{"key":"10.1016\/j.survophthal.2023.09.007_bib71","unstructured":"213736s002lbl.pdf [Internet]. [cited 2023 January 16]. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213736s002lbl.pdf\u3009."}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625723001285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625723001285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:57:44Z","timestamp":1758542264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625723001285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0039625723001285"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2023.09.007","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular toxicities of fibroblast growth factor receptor inhibitors: A review","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2023.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}